[go: up one dir, main page]

GB201020671D0 - Passive immunotherapy - Google Patents

Passive immunotherapy

Info

Publication number
GB201020671D0
GB201020671D0 GBGB1020671.2A GB201020671A GB201020671D0 GB 201020671 D0 GB201020671 D0 GB 201020671D0 GB 201020671 A GB201020671 A GB 201020671A GB 201020671 D0 GB201020671 D0 GB 201020671D0
Authority
GB
United Kingdom
Prior art keywords
passive immunotherapy
antibodies
tuberculosis
exclusively
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1020671.2A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
University of Dundee
Original Assignee
Kings College London
University of Dundee
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London, University of Dundee filed Critical Kings College London
Priority to GBGB1020671.2A priority Critical patent/GB201020671D0/en
Publication of GB201020671D0 publication Critical patent/GB201020671D0/en
Priority to PCT/GB2011/052404 priority patent/WO2012076868A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to antibodies to Mycobacterium tuberculosis, and to methods, compositions and cells associated with such antibodies. Such antibodies are useful of the treatment of tuberculosis, particularly but not exclusively through passive immunotherapy.
GBGB1020671.2A 2010-12-07 2010-12-07 Passive immunotherapy Ceased GB201020671D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB1020671.2A GB201020671D0 (en) 2010-12-07 2010-12-07 Passive immunotherapy
PCT/GB2011/052404 WO2012076868A1 (en) 2010-12-07 2011-12-06 Antibodies to mycobacteria

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1020671.2A GB201020671D0 (en) 2010-12-07 2010-12-07 Passive immunotherapy

Publications (1)

Publication Number Publication Date
GB201020671D0 true GB201020671D0 (en) 2011-01-19

Family

ID=43531554

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1020671.2A Ceased GB201020671D0 (en) 2010-12-07 2010-12-07 Passive immunotherapy

Country Status (2)

Country Link
GB (1) GB201020671D0 (en)
WO (1) WO2012076868A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10414819B2 (en) 2013-08-30 2019-09-17 Longhorn Vaccines And Diagnostics, Llc Monoclonal antibodies that modulate immunity to MTB and enhance immune clearance
US10370437B2 (en) 2013-08-30 2019-08-06 Longhorn Vaccines And Diagnostics, Llc Antibodies that modulate immunity to drug resistant and latent MTB infections
AU2014312135B2 (en) * 2013-08-30 2017-09-07 Longhorn Vaccines And Diagnostics, Llc Enhancing immunity to tuberculosis
WO2022034513A1 (en) * 2020-08-12 2022-02-17 Università Cattolica del Sacro Cuore Composition for use in the treatment of respiratory infection caused by coronavirus

Also Published As

Publication number Publication date
WO2012076868A1 (en) 2012-06-14

Similar Documents

Publication Publication Date Title
MX2013001473A (en) Antibodies against il-18r1 and uses thereof.
PH12013500360B1 (en) Pesticidal compositions
MX2015005944A (en) Microbial strains, compositions, and methods for increasing available phosphate for plants.
MX2013001045A (en) Liver organoid, uses thereof and culture method for obtaining them.
PH12014501427B1 (en) Anti-phf-tau antibodies and their uses
MX345909B (en) Anti-fgfr3 antibodies and methods using same.
MX336001B (en) Anti-axl antibodies and methods of use.
MX2013011479A (en) Anti-fgfr4 antibodies and methods of use.
MX2014002053A (en) Anti-mcsp antibodies.
MY181898A (en) Heterocyclic compounds and uses thereof
GB2492305A (en) Polymers of benzodithiophene and their use as organic semiconductors
PH12014500841B1 (en) ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
TN2012000366A1 (en) Anticoagulant antidotes
CA2866116C (en) Expansion of alloantigen-reactive regulatory t cells
MX336323B (en) Anti-polyubiquitin antibodies and methods of use.
AU2014233478A8 (en) Anti-CD25 antibodies and their uses
PH12015501059A1 (en) Anti-hemagglutinin antibodies and methods of use
MX2014014376A (en) Anti-biotin antibodies and methods of use.
MX337203B (en) Novel jnk inhibitor molecules.
MX2015012563A (en) Anti-cd25 antibodies and their uses.
PH12013501311A1 (en) Polymer systems
WO2014097318A3 (en) Agents for eliminating tumour-initiating cells
MX381841B (en) Anti-jagged anitbodies and methods of use
GB201020671D0 (en) Passive immunotherapy
MX363385B (en) Treatment of sickle cell disease and inflammatory conditions.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)